Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer discussed the wide-spread applicability of scalp EEG and the potential for machine learning models to help predict epilepsy surgery outcomes. [WATCH TIME: 4 minutes]

Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS

Articles

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

Medication Compliance High With Self-Administered Ziluocoplan in Myasthenia Gravis

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

Negative Effect of Deferiprone Points to Impact of Iron Lowering in Alzheimer Disease

The findings suggest that future phase 3 trials should explore the duration of pain relief and headache recurrence, with the goal of developing structured treatment guidelines for PTH.

Sumatriptan Demonstrates Therapeutic Potential in Post-Traumatic Headache in Phase 2 Pilot Study

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Phase 2a Trial to Test Effects of Antiseizure Medication Lamotrigine in Dementia With Lewy Bodies

Dean and chief academic officer at the University of Miami Miller School of Medicine.

The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]

Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA 

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Research from IJMSC September 2024

William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology; Chair, Neurology; Neurologist-in-Chief, Yale New Haven Hospital

The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about the ongoing evolution of multiple sclerosis diagnostic criteria and the importance of comprehensive testing to guide early intervention and improve outcomes. [WATCH TIME: 5 minutes]

Evolution of Multiple Sclerosis Diagnostic Criteria and the Role of Spinal Taps: David A. Hafler, MD, FANA

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Cure SMA

SAP Partners

Episode 1: Overview of Telehealth in Clinical Practice and Patient Options

Episode 2: How Telehealth Can Improve Care for Patients With SMA

Episode 3: Utilizing Telehealth to Conduct Multidisciplinary Visits in SMA Care

Episode 4: The Limitations of Telehealth for Treating SMA

Episode 5: The COVID-19 Pandemic's Effect on Telehealth Use for SMA

Episode 6: Easing the Process of Learning to Use, Incorporate Telehealth in Practice

Episode 7: Prepping Patients With SMA and Their Families Prior to Telehealth Visits

Episode 8: Proposed Solutions to the Limitations of Telehealth

Episode 9: Maximizing Patient Engagement During Telehealth Visits

Episode 10: How Telehealth Provides Insight, Perspective on At-Home Challenges

Episode 11: Resources Available for Patients With SMA 

Cure SMA is dedicated to the treatment and care of spinal muscular atrophy (SMA). Since 1984, Cure SMA has grown to be the largest network of individuals, families, clinicians, and research scientists working together to advance SMA research, support the full SMA community, and educate the public and professional communities about SMA. The organization has directed and invested in comprehensive research that has shaped the scientific community's understanding of SMA, led to breakthroughs in treatment and care, and provides individuals and families the support they need today. For more information, visit 

SAP Partner

Clinical

Lessons Learned in Telehealth When Implementing Multidisciplinary Care for Patients Affected by SMA